The U.S. Food and Drug Administration (FDA) has issued a safety warning regarding the over-the-counter weight loss medication Alli, citing a potential link to acute kidney injury. According to the agency, a review of safety reports identified 12 cases of kidney complications associated with the drug, which uses orlistat as its active ingredient. Federal regulators are now advising individuals with a history of kidney disease or stones to consult a healthcare provider before use.
What are the risks associated with Alli?
The FDA reports that while the risk of kidney injury is rare, it can be serious. The agency’s updated labeling warns consumers to stop taking the medication and seek medical attention if they experience symptoms such as back or groin pain, painful urination, blood in the urine, or swelling in the feet and legs. According to the FDA, untreated cases of acute kidney injury can be fatal, and nearly 570,000 deaths were linked to the condition between 2018 and 2023.
Alli was the first over-the-counter weight loss pill approved by the FDA, receiving authorization in 2007. It functions by inhibiting the digestive enzyme lipase, which prevents the body from absorbing approximately 25% of dietary fat.
How does Alli compare to modern GLP-1 drugs?
The mechanism of action for Alli differs significantly from the current generation of weight loss treatments, such as Ozempic and Wegovy. While Alli targets fat absorption in the intestines, GLP-1 medications use semaglutide to mimic hormones that suppress appetite. According to Novo Nordisk, at least three million people have received prescriptions for Wegovy since January. Unlike Alli, which is taken up to three times daily with meals, GLP-1 drugs are generally administered via weekly injections or daily pills.
Recent Safety History and Counterfeit Concerns
This is not the first time Alli has undergone regulatory scrutiny. In 2010, the FDA investigated reports of potential liver injury, though the Mayo Clinic notes that the review found no conclusive evidence linking the drug to those specific adverse events. Beyond clinical safety, consumers face risks from counterfeit versions of the product. The FDA has previously warned that some illicit versions of the pill contain sibutramine, a compound previously linked to an increased risk of stroke and heart attack.
Frequently Asked Questions
- Is the prescription version of Alli safer? No. The prescription version, known as Xenical, carries similar kidney health risks as the nonprescription dosage, according to the FDA.
- Can kidney injury from Alli be reversed? Mild cases of acute kidney injury may be reversible, but the FDA stresses that the condition can become fatal if left untreated.
- Who should avoid taking Alli? The FDA recommends that individuals with a history of kidney stones or kidney disease consult a physician before starting the medication.
For more updates on consumer health and regulatory news, subscribe to our weekly newsletter or join the conversation in the comments section below.
